Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) have been given an average recommendation of “Moderate Buy” by the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $15.75.

Several equities research analysts have recently weighed in on the company. Oppenheimer reduced their price objective on Ventyx Biosciences from $12.00 to $10.00 and set an “outperform” rating for the company in a research report on Thursday, June 6th. HC Wainwright reissued a “neutral” rating and issued a $6.00 price target on shares of Ventyx Biosciences in a research report on Thursday, June 13th.

Hedge Funds Weigh In On Ventyx Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of VTYX. China Universal Asset Management Co. Ltd. boosted its stake in Ventyx Biosciences by 66.6% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,385 shares of the company’s stock worth $63,000 after acquiring an additional 4,553 shares during the last quarter. Norden Group LLC bought a new stake in shares of Ventyx Biosciences during the 1st quarter worth approximately $59,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Ventyx Biosciences in the first quarter valued at $72,000. SG Americas Securities LLC acquired a new stake in Ventyx Biosciences in the 2nd quarter valued at about $32,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of Ventyx Biosciences by 1,424.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 19,927 shares of the company’s stock valued at $49,000 after buying an additional 18,620 shares during the last quarter. 97.88% of the stock is owned by institutional investors.

Ventyx Biosciences Stock Performance

Shares of NASDAQ VTYX opened at $2.84 on Friday. The business has a 50 day simple moving average of $3.30 and a 200 day simple moving average of $4.15. Ventyx Biosciences has a 52 week low of $1.87 and a 52 week high of $38.20. The stock has a market cap of $200.22 million, a price-to-earnings ratio of -0.88 and a beta of 0.39.

Ventyx Biosciences (NASDAQ:VTYX) last announced its earnings results on Thursday, May 9th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.05. During the same period in the prior year, the firm posted ($0.68) EPS. On average, analysts predict that Ventyx Biosciences will post -2.31 EPS for the current year.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.